Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas

NCT03179930 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Relapsed
Refractory

Interventions

DRUG: Entinostat
DRUG: Pembrolizumab

Sponsor

Memorial Sloan Kettering Cancer Center

Collaborators

[object Object]
[object Object]